文献速递多重用药老年慢病共病管理

老年人多重用药与全因及病因别死亡率的剂量反应关系

Dose-Response Relationships Between Polypharmacy and All-Cause and Cause-Specific Mortality Among Older People.
PubMed 文献 · J Gerontol A Biol Sci Med Sci · 2022-01-01

结果显示两种用药水平均与全因死亡和心血管病死亡风险升高相关,癌症死亡仅与重度多重用药相关。作者建议对老年人多重用药给予更广泛关注。

要点

  • 多重用药(5-9种)和重度多重用药(10种及以上)均与全因死亡风险升高相关。
  • 两种用药水平均与心血管病死亡风险升高相关,癌症死亡仅与重度多重用药相关。
  • 结果独立于人口学因素、严重疾病、长期状况、认知功能和抑郁。

核心结论

  • 多重用药和重度多重用药均与全因死亡和心血管病死亡风险升高相关,癌症死亡仅与重度多重用药相关。
  • 作者建议对老年人多重用药给予更广泛关注,而不仅限于重度多重用药。

研究设计与样本

  • 英国老龄化纵向研究(ELSA)为全国代表性研究,纳入50岁及以上人群。
  • 多重用药定义为每日长期服用5-9种药物,重度多重用药定义为10种及以上。
  • 采用Cox比例风险回归和竞争风险回归分别分析全因和病因别死亡关联。

主要发现

  • 随访6年期间,与未用药者相比,多重用药(19.3%)的全因死亡风险比为1.51(95%CI:1.05-2.16)。
  • 重度多重用药(2.4%)的全因死亡风险比为2.29(95%CI:1.40-3.75)。
  • 多重用药和重度多重用药的心血管病死亡风险比分别为2.45(95%CI:1.13-5.29)和3.67(95%CI:1.43-9.46)。
  • 癌症死亡仅与重度多重用药相关。

关键数值与推荐

  • 多重用药:每日长期服用5-9种药物;重度多重用药:每日长期服用10种及以上药物。
  • 全因死亡风险比:多重用药1.51(95%CI:1.05-2.16),重度多重用药2.29(95%CI:1.40-3.75)。
  • 心血管病死亡风险比:多重用药2.45(95%CI:1.13-5.29),重度多重用药3.67(95%CI:1.43-9.46)。

临床怎么用

  • 对老年人多重用药(5-9种)也应关注并考虑结构化药物审查,而不仅限于重度多重用药。
  • 处方时应权衡多重用药与全因死亡及心血管病死亡风险升高的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although medicines are prescribed based on clinical guidelines and expected to benefit patients, both positive and negative health outcomes have been reported associated with polypharmacy. Mortality is the main outcome, and information on cause-specific mortality is scarce. Hence, we investigated the association between different levels of polypharmacy and all-cause and cause-specific mortality among older adults. METHOD: The English Longitudinal Study of Ageing is a nationally representative study of people aged 50+. From 2012/2013, 6 295 individuals were followed up to April 2018 for all-cause and cause-specific mortality. Polypharmacy was defined as taking 5-9 long-term medications daily and heightened polypharmacy as 10+ medications. Cox proportional hazards regression and competing-risks regression were used to examine associations between polypharmacy and all-cause and cause-specific mortality, respectively. RESULTS: Over a 6-year follow-up period, both polypharmacy (19.3%) and heightened polypharmacy (2.4%) were related to all-cause mortality, with hazard ratios of 1.51 (95% CI: 1.05-2.16) and 2.29 (95% CI: 1.40-3.75) respectively, compared with no medications, independently of demographic factors, serious illnesses and long-term conditions, cognitive function, and depression. Polypharmacy and heightened polypharmacy also showed 2.45 (95% CI: 1.13-5.29) and 3.67 (95% CI: 1.43-9.46) times higher risk of cardiovascular disease deaths, respectively. Cancer mortality was only related to heightened polypharmacy. CONCLUSION: Structured medication reviews are currently advised for heightened polypharmacy, but our results suggest that greater attention to polypharmacy in general for older people may reduce adverse effects and improve older adults' health.

来源:J Gerontol A Biol Sci Med Sci,查看原文。版权归原作者所有。

引用

  1. Huang YT, Steptoe A, Wei L, et al. Dose-Response Relationships Between Polypharmacy and All-Cause and Cause-Specific Mortality Among Older People. J Gerontol A Biol Sci Med Sci. 2022. PMID: 34079992. doi:10.1093/gerona/glab155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。